Cognizant's Shared Investigator Platform Grows to More Than a Quarter Million Users Globally

Rhea-AI Summary

Cognizant (NASDAQ: CTSH) announced that its Shared Investigator Platform (SIP) has reached over 250,000 users in more than 100 countries. Launched in 2016, SIP streamlines clinical trials by standardizing documents and facilitating collaboration among biopharmaceutical organizations. Utilization has surged by over 65% in the last two years, with SIP currently in use by seven major global biopharmaceutical firms. The platform expedites drug discovery and has been recognized by organizations like the UK's NIHR for enhancing research efficiency.

Positive

• SIP has surpassed 250,000 users, indicating strong market adoption.
• Utilization of SIP has increased by over 65% in the last two years.
• SIP is used by seven of the largest global biopharmaceutical companies, enhancing its credibility.
• The platform reduces feasibility questionnaire completion times by 36%, accelerating clinical trials.

Negative

• None.

Digital Platform is Helping Accelerate Drug Discovery and Influence Improved Healthcare by Modernizing Clinical Trials

TEANECK, N.J., Sept. 20, 2022 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution that streamlines clinical trials to improve the speed of pharmaceutical drug discovery, has surpassed 250,000 users across 100 countries worldwide. This digital platform facilitates research and collaboration around the globe by allowing clinical study documents and safety notifications to be easily and securely exchanged across site and sponsor teams.

SIP was established in 2016 as part of a joint effort between Cognizant and TransCelerate, a consortium of the world's largest biopharmaceutical organizations, to standardize clinical trial documents, training and start-up activities into a single shared environment to reduce costs and increase efficiency. Today, SIP is in use by 7 of the largest global biopharmaceutical companies, including Merck. Currently in operation at over 32,000 trial-ready sites, SIP's utilization has increased by more than 65% in the last two years.

"As one of the original sponsors using the platform, we're pleased to see SIP reach this growth milestone," said Jennifer Sheller, Clinical Trial Operations at Merck Research Laboratories. "We look forward to the continued evolution of the platform, with the collective aim of improving efficiency by reuse of commonly requested site information across sponsors and securing access to Good Clinical Practice (GCP) required documents via SIP."

SIP has been crucial in connecting clinical trial sponsors and research sites, leveraging automation and remote access technology. In one recent example, SIP helped reduce feasibility questionnaire completion times by 36%, allowing clinical trials to begin more quickly and thereby helping accelerate the time to market for new therapeutics.* In addition to commercial enterprise, government organizations, including the United Kingdom's National Institute for Health and Care Research (NIHR), have praised SIP for its approach to life sciences research.

"NIHR is supportive of using streamlined technology to promote and place research across the health and care system for the benefit of patients," said Dr Ginette Hoare, Industry Operations Manager at NIHR Clinical Research Network North Thames. "At NIHR Local Clinical Research Network North Thames, we feel it is important to support our National Health Service research sites to develop their structures and profiles, within platforms such as SIP, to increase their visibility to commercial sponsors, streamline clinical research processes and to maximize the potential opportunities to participate in commercial contract research."

"As the world continues to fight new disease outbreaks, the ability for Biopharmaceutical and Clinical and Academic Research organizations to collaborate virtually has become more important than ever," said Surya Gummadi, Cognizant's SVP of Global Health Sciences and SVP, Americas. "The speed and efficiency that SIP enables is critical in reducing administrative burdens and expediting the pace at which new life-saving therapies can be brought to market. Cognizant is proud to be a leader in helping the biopharmaceutical industry leverage new technologies, including the cloud, to advance drug discovery and support global health needs."

*https://www.cognizant.com/us/en/thought-leadership/documents/roche-cuts-feasibility-process-by-36-percent-codex6804.pdf

To learn more about Cognizant's Shared Investigator Platform: https://www.cognizant.com/shared-investigator-platform

About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.

For more information, contact:

U.S. Josh Blumenthal Joshua.Blumenthal@Cognizant.com

Europe / APAC Christina Schneider Christina.Schneider@Cognizant.com

India Rashmi Vasisht Rashmi.Vasisht@Cognizant.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cognizants-shared-investigator-platform-grows-to-more-than-a-quarter-million-users-globally-301627777.html

SOURCE Cognizant

FAQ

What is Cognizant's Shared Investigator Platform (SIP)?

Cognizant's Shared Investigator Platform (SIP) is a SaaS solution that standardizes clinical trial processes to improve the speed and efficiency of drug discovery.

How many users does Cognizant's SIP have?

SIP has surpassed 250,000 users across more than 100 countries.

When was the Shared Investigator Platform launched?

SIP was launched in 2016.

Which companies are using Cognizant's SIP?

SIP is currently utilized by seven of the largest global biopharmaceutical companies, including Merck.

What recent achievements has Cognizant's SIP accomplished?

The platform has increased its utilization by over 65% in the last two years and has helped reduce feasibility questionnaire completion times by 36%.